Flagship Pioneering-backed Profound Therapeutics Inc. made its debut with $75 million from its originator to support ongoing efforts with the Profoundry platform, which the company said has led to the discovery of tens of thousands of novel proteins as part of an ambitious plan for “remapping the landscape of the human genome.” Read More
Interim phase I data from 16 patients with refractory metastatic uveal melanoma provide a tantalizing hint that Ionctura SA’s phosphoinositide 3-kinase (PI3K) delta inhibitor IOA-244 PI3 may offer a survival benefit. Thirteen of the 16 patients –
81.25% – remained alive and on therapy after 12 months of treatment. All had received one or more prior therapies. Read More
Ignoring congressional sentiment, U.S. Health and Human Services Secretary Xavier Becerra announced the formal establishment of the Advanced Research Project Agency for Health as an independent entity within the NIH. Read More
Nurix Therapeutics Inc. has started its first phase Ib expansion cohort for treating chronic lymphocytic leukemia with NX-2127 but it is facing the headwind of a drop in share price. Shares (NASDAQ:NRIX) of the San Francisco-based company closed 22.7% lower at $7.88 each on May 26. Share prices in the past 12 months have drifted lower since their crest of $26.69 each on Sept. 9, 2021. Read More
Goldman Sachs Group Inc.’s private equity arm has agreed to buy a controlling stake in specialty pharma Norgine BV from the company’s founding Stein family. Financial terms were not disclosed. Read More
A lengthy trial over two generic drug manufacturers’ alleged role in fueling the opioid epidemic in West Virginia came to an end this week when the U.S. affiliate of Teva Pharmaceuticals Ltd. and Allergan, now part of Abbvie Inc., agreed to a settlement totaling more than $161.5 million. Read More
New and updated preclinical and clinical data presented by biopharma firms at Digestive Disease Week 2022, including: Ardelyx, Ferring, Ironwood, Janssen, Phathom, Rebiotix, Redhill, Second Genome. Read More
Biopharmas raising money in public or private financings, including: Amytrx, Full-Life Technologies, Geovax Labs, Neuvivo, Profound, Rapid Dose. Read More
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Codagenix, Crinetics, Endeavor, Harbour, Junshi, Karyopharm, Obseva, Osivax, Pharmazz. Read More
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Ellipses, Enlivex, Evgen, Insilico, Merck, Novocure, Novomedix, Oxford. Read More
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Alzecure, Cornerstone, Elevation, Jaguar, Medac, Medexus, Oncotelic, Phathom, Verrica. Read More
